Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
AUPH
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.18
vs -0.27
Q2.23
N/A
-0.08
vs -0.25
Q3.23
N/A
-0.09
vs -0.06
Q4.23
N/A
-0.19
vs -0.18
Q1.24
N/A
-0.03
vs -0.18
Q2.24
+125%
0.02
vs -0.08
Q3.24
+211%
0.1
vs -0.09
Q4.24
+147%
0.09
vs -0.19
Q1.25
+433%
0.1
vs -0.03
Q2.25
+440%
0.11
vs 0.02
Sales Growth
YoY
Current
Estimates
Q1.23
+59%
34.4M vs 21.6M
Q2.23
+47%
41.5M vs 28.2M
Q3.23
-2%
54.5M vs 55.8M
Q4.23
+59%
45.1M vs 28.4M
Q1.24
+46%
50.3M vs 34.4M
Q2.24
+38%
57.2M vs 41.5M
Q3.24
+24%
67.8M vs 54.5M
Q4.24
+33%
59.9M vs 45.1M
Q1.25
+21%
61.1M vs 50.3M
Q2.25
+13%
64.4M vs 57.2M
Return on Equity
QoQ
Q1.23
-7%
-0.07
vs -0.06
Q2.23
-3%
-0.03
vs -0.07
Q3.23
-3%
-0.03
vs -0.03
Q4.23
-7%
-0.07
vs -0.03
Q1.24
-3%
-0.03
vs -0.07
Q2.24
+0%
0
vs -0.03
Q3.24
+4%
0.04
vs 0
Q4.24
+0%
0
vs 0.04
Institutionnal Ownership
QoQ
Q1.23
202
202
vs 211
-4%
Q2.23
219
219
vs 202
8%
Q3.23
217
217
vs 219
-1%
Q4.23
210
210
vs 217
-3%
Q1.24
197
197
vs 210
-6%
Q2.24
181
181
vs 197
-8%
Q3.24
197
197
vs 181
9%
Q4.24
214
214
vs 197
9%
Forecast
332%2025-Revenue
4360%2025-EPS
-2258%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Oppenheimer
upgradePrevious: Not converted
2021-12-10
Now: Outperform
businesswire.com
6 hours ago
businesswire.com
6 hours ago
businesswire.com
6 hours ago
247wallst.com
8 hours ago
seekingalpha.com
10 hours ago
zacks.com
10 hours ago
Relative Strength
AUPH
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
NASDAQ
Relative Strenght
90
Volume Buzz
-35%
Earning Acce
No
Dist 52w H.
24%